VANCOUVER, British Columbia, June 4, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented additional clinical results from an extension study of its Phase 1 human clinical trial with ALN-VSP, an RNAi therapeutic for the treatment of advanced solid tumors with liver involvement, which utilizes Tekmira’s lipid nanoparticle (LNP) technology and is manufactured by Tekmira.
